Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Thoracic 1Other solid neoplasm 1Breast 1

Conditions

Mesothelioma, Malignant 2Solid Tumor, Adult 1Solid Tumor 1Sarcoma 1Retinoblastoma 1Osteosarcoma 1Neoplasm Metastasis 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Filgrastim 2Carboplatin 2ribociclib 1enzalutamide 1belinostat 1becatecarin 1abemaciclib 1Topotecan 1Thiotepa 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Pemetrexed 1Midazolam 1Letrozole 1LY3023414 1Immunotherapy, Adoptive 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1Fulvestrant 1Etoposide 1Doxepin 1Cisplatin 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × abemaciclib × Other solid neoplasm × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡